Stoke Therapeutics (STOK) Projected to Post Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) is expected to be posting its Q4 2024 quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Stoke Therapeutics to post earnings of ($0.56) per share and revenue of $4.20 million for the quarter.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, analysts expect Stoke Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Stoke Therapeutics Trading Down 1.1 %

NASDAQ:STOK traded down $0.09 during mid-day trading on Thursday, hitting $8.17. The stock had a trading volume of 614,389 shares, compared to its average volume of 831,536. The stock has a market capitalization of $432.74 million, a price-to-earnings ratio of -3.88 and a beta of 0.99. The company has a 50 day simple moving average of $9.50 and a 200-day simple moving average of $11.51. Stoke Therapeutics has a 52 week low of $5.60 and a 52 week high of $17.58.

Analyst Upgrades and Downgrades

A number of research firms have commented on STOK. HC Wainwright restated a "buy" rating and set a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Chardan Capital restated a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $23.00.

Remove Ads

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.